1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Opioid-Induced Constipation Revenue
1.4 Market Analysis by Type
1.4.1 Global Opioid-Induced Constipation Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Methylnaltrexone Bromide
1.4.3 Lubiprostone
1.4.4 Naloxegol
1.4.5 Others
1.5 Market by Application
1.5.1 Global Opioid-Induced Constipation Market Share by Application: 2021-2026
1.5.2 Hospital
1.5.3 Pharmacy
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Opioid-Induced Constipation Market
1.8.1 Global Opioid-Induced Constipation Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Opioid-Induced Constipation Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Opioid-Induced Constipation Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Opioid-Induced Constipation Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Opioid-Induced Constipation Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Opioid-Induced Constipation Sales Volume Market Share by Region (2015-2020)
3.2 Global Opioid-Induced Constipation Sales Revenue Market Share by Region (2015-2020)
3.3 North America Opioid-Induced Constipation Sales Volume
3.3.1 North America Opioid-Induced Constipation Sales Volume Growth Rate (2015-2020)
3.3.2 North America Opioid-Induced Constipation Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Opioid-Induced Constipation Sales Volume
3.4.1 East Asia Opioid-Induced Constipation Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Opioid-Induced Constipation Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Opioid-Induced Constipation Sales Volume (2015-2020)
3.5.1 Europe Opioid-Induced Constipation Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Opioid-Induced Constipation Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Opioid-Induced Constipation Sales Volume (2015-2020)
3.6.1 South Asia Opioid-Induced Constipation Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Opioid-Induced Constipation Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Opioid-Induced Constipation Sales Volume (2015-2020)
3.7.1 Southeast Asia Opioid-Induced Constipation Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Opioid-Induced Constipation Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Opioid-Induced Constipation Sales Volume (2015-2020)
3.8.1 Middle East Opioid-Induced Constipation Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Opioid-Induced Constipation Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Opioid-Induced Constipation Sales Volume (2015-2020)
3.9.1 Africa Opioid-Induced Constipation Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Opioid-Induced Constipation Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Opioid-Induced Constipation Sales Volume (2015-2020)
3.10.1 Oceania Opioid-Induced Constipation Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Opioid-Induced Constipation Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Opioid-Induced Constipation Sales Volume (2015-2020)
3.11.1 South America Opioid-Induced Constipation Sales Volume Growth Rate (2015-2020)
3.11.2 South America Opioid-Induced Constipation Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Opioid-Induced Constipation Sales Volume (2015-2020)
3.12.1 Rest of the World Opioid-Induced Constipation Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Opioid-Induced Constipation Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Opioid-Induced Constipation Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Opioid-Induced Constipation Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Opioid-Induced Constipation Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Opioid-Induced Constipation Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Opioid-Induced Constipation Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Opioid-Induced Constipation Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Opioid-Induced Constipation Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Opioid-Induced Constipation Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Opioid-Induced Constipation Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Opioid-Induced Constipation Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Opioid-Induced Constipation Sales Volume Market Share by Type (2015-2020)
14.2 Global Opioid-Induced Constipation Sales Revenue Market Share by Type (2015-2020)
14.3 Global Opioid-Induced Constipation Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Opioid-Induced Constipation Consumption Volume by Application (2015-2020)
15.2 Global Opioid-Induced Constipation Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Opioid-Induced Constipation Business
16.1 Takeda Pharmaceuticals
16.1.1 Takeda Pharmaceuticals Company Profile
16.1.2 Takeda Pharmaceuticals Opioid-Induced Constipation Product Specification
16.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Purdue Pharm
16.2.1 Purdue Pharm Company Profile
16.2.2 Purdue Pharm Opioid-Induced Constipation Product Specification
16.2.3 Purdue Pharm Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Mallinckrodt
16.3.1 Mallinckrodt Company Profile
16.3.2 Mallinckrodt Opioid-Induced Constipation Product Specification
16.3.3 Mallinckrodt Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Bayer
16.4.1 Bayer Company Profile
16.4.2 Bayer Opioid-Induced Constipation Product Specification
16.4.3 Bayer Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Progenics Pharmaceuticals
16.5.1 Progenics Pharmaceuticals Company Profile
16.5.2 Progenics Pharmaceuticals Opioid-Induced Constipation Product Specification
16.5.3 Progenics Pharmaceuticals Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Sanofi
16.6.1 Sanofi Company Profile
16.6.2 Sanofi Opioid-Induced Constipation Product Specification
16.6.3 Sanofi Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 Daiichi Sankyo
16.7.1 Daiichi Sankyo Company Profile
16.7.2 Daiichi Sankyo Opioid-Induced Constipation Product Specification
16.7.3 Daiichi Sankyo Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 AstraZeneca
16.8.1 AstraZeneca Company Profile
16.8.2 AstraZeneca Opioid-Induced Constipation Product Specification
16.8.3 AstraZeneca Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Salix (Bausch Health)
16.9.1 Salix (Bausch Health) Company Profile
16.9.2 Salix (Bausch Health) Opioid-Induced Constipation Product Specification
16.9.3 Salix (Bausch Health) Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 Nektar Therapeutics
16.10.1 Nektar Therapeutics Company Profile
16.10.2 Nektar Therapeutics Opioid-Induced Constipation Product Specification
16.10.3 Nektar Therapeutics Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.11 Prestige
16.11.1 Prestige Company Profile
16.11.2 Prestige Opioid-Induced Constipation Product Specification
16.11.3 Prestige Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.12 GSK
16.12.1 GSK Company Profile
16.12.2 GSK Opioid-Induced Constipation Product Specification
16.12.3 GSK Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.13 Shionogi
16.13.1 Shionogi Company Profile
16.13.2 Shionogi Opioid-Induced Constipation Product Specification
16.13.3 Shionogi Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Opioid-Induced Constipation Manufacturing Cost Analysis
17.1 Opioid-Induced Constipation Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Opioid-Induced Constipation
17.4 Opioid-Induced Constipation Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Opioid-Induced Constipation Distributors List
18.3 Opioid-Induced Constipation Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Opioid-Induced Constipation (2021-2026)
20.2 Global Forecasted Revenue of Opioid-Induced Constipation (2021-2026)
20.3 Global Forecasted Price of Opioid-Induced Constipation (2015-2026)
20.4 Global Forecasted Production of Opioid-Induced Constipation by Region (2021-2026)
20.4.1 North America Opioid-Induced Constipation Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Opioid-Induced Constipation Production, Revenue Forecast (2021-2026)
20.4.3 Europe Opioid-Induced Constipation Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Opioid-Induced Constipation Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Opioid-Induced Constipation Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Opioid-Induced Constipation Production, Revenue Forecast (2021-2026)
20.4.7 Africa Opioid-Induced Constipation Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Opioid-Induced Constipation Production, Revenue Forecast (2021-2026)
20.4.9 South America Opioid-Induced Constipation Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Opioid-Induced Constipation Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Opioid-Induced Constipation by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Opioid-Induced Constipation by Country
21.2 East Asia Market Forecasted Consumption of Opioid-Induced Constipation by Country
21.3 Europe Market Forecasted Consumption of Opioid-Induced Constipation by Countriy
21.4 South Asia Forecasted Consumption of Opioid-Induced Constipation by Country
21.5 Southeast Asia Forecasted Consumption of Opioid-Induced Constipation by Country
21.6 Middle East Forecasted Consumption of Opioid-Induced Constipation by Country
21.7 Africa Forecasted Consumption of Opioid-Induced Constipation by Country
21.8 Oceania Forecasted Consumption of Opioid-Induced Constipation by Country
21.9 South America Forecasted Consumption of Opioid-Induced Constipation by Country
21.10 Rest of the world Forecasted Consumption of Opioid-Induced Constipation by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer